abstract |
The present invention provides some bridged ring compounds as shown in formula (I) or their stereoisomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs , for the treatment of hepatitis C virus (HCV) infection or hepatitis C disease. The present invention also discloses pharmaceutical compositions containing such compounds and methods of treating HCV infection or hepatitis C disease using the compounds of the present invention or pharmaceutical compositions thereof. |